Justin D. Schumacher, Bo Kong, Jason Wu, Daniel Rizzolo, Laura E. Armstrong, Monica D. Chow, Michael Goedken, Yi‐Horng Lee, Grace L. Guo – 17 June 2019 – Farnesoid X receptor (FXR) induces fibroblast growth factor 15 (FGF15; human ortholog FGF19) in the gut to potently inhibit bile acid (BA) synthesis in the liver. FXR activation in hepatic stellate cells (HSCs) reduces liver fibrosis (LF). Fgf15–/– mice develop attenuated LF, but the underlying mechanisms for this protection are unclear.

Jin Sil Kim, Kyoung Won Kim, Jeongjin Lee, Heon‐Ju Kwon, Jae Hyun Kwon, Gi Won Song, Sung Gyu Lee – 17 June 2019 – The purpose of this study was to compare the diagnostic performance of computed tomography angiography (CTA) and contrast‐enhanced ultrasound (CEUS) when used to diagnose significant hepatic artery occlusion (HAO) in patients that was suspected on Doppler ultrasound (US). Among 3465 adult liver transplantations (LTs) performed between January 2010 and February 2018, 329 recipients were suspected of having HAO by Doppler US.

Karen L. Swanson – 17 June 2019

** VIEW ONLY CONTENT . The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". ** The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

Suet‐Yan Kwan, Ankur Sheel, Chun‐Qing Song, Xiao‐Ou Zhang, Tingting Jiang, Hien Dang, Yueying Cao, Deniz M. Ozata, Haiwei Mou, Hao Yin, Zhiping Weng, Xin Wei Wang, Wen Xue – 12 June 2019 – Hepatocellular carcinoma (HCC) is an aggressive subtype of liver cancer with few effective treatments, and the underlying mechanisms that drive HCC pathogenesis remain poorly characterized. Identifying genes and pathways essential for HCC cell growth will aid the development of new targeted therapies for HCC.

Kristopher P. Croome, David D. Lee, Sarah Croome, Raouf E. Nakhleh, Peter Abader Sedki Senada, David Livingston, Maria Yataco, C. Burcin Taner – 12 June 2019 – It has been suggested that microsteatosis does not negatively impact graft survival following liver transplantation (LT). The present study represents the largest series on donor livers with significant microsteatosis and investigates the impact of microsteatosis on perioperative factors such as postreperfusion syndrome (PRS), early allograft dysfunction (EAD), and postoperative renal dysfunction.

George N. Ioannou, Pamela K. Green, Kristin Berry, Solomon A. Graf – 11 June 2019 – It is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignancies.

Camila C. Simoes, Omar A. Saldarriaga, Netanya S. Utay, Ashley E. Stueck, Sheharyar K. Merwat, Shehzad N. Merwat, Thomas D. Schiano, Maria Isabel Fiel, Heather L. Stevenson – 8 June 2019 – Patients with hepatitis C virus (HCV) often have elevated serum markers and histologic features of autoimmune hepatitis (AIH). We evaluated an HCV‐positive (HCV+) study group that had elevated serum markers of AIH before starting direct‐acting antiviral (DAA) therapy (n = 21) and compared them to an HCV+ control group that did not have laboratory studies suggesting AIH (n = 21).

Qiupeng Zheng, Jingjing Zhao, Hui Yu, Huajie Zong, Xigan He, Yiming Zhao, Yan Li, Yu Wang, Yichao Bao, Yuchen Li, Bing Chen, Weijie Guo, Yilin Wang, Zhiao Chen, Yingjun Zhao, Lu Wang, Xianghuo He, Shenglin Huang – 7 June 2019 – Hepatocellular carcinoma (HCC) is a highly lethal cancer and its underlying etiology remains understudied. The immense diversity and complexity of the cancer transcriptome hold the potential to yield tumor‐specific transcripts (TSTs).

Pegah Golabi, Natsu Fukui, James Paik, Mehmet Sayiner, Alita Mishra, Zobair M. Younossi – 6 June 2019 – Cardiovascular diseases (CVDs) are the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Our aim was to assess the association of atherosclerotic cardiovascular disease (ASCVD) risk scores with overall and cardiac‐specific mortality among patients with NAFLD. We used the National Health and Nutrition Examination Survey III with the National Death Index‐linked mortality files.